Given its role in cancer progression, PLC is considered a potential therapeutic target. Inhibitors of PLC activity can reduce tumor growth and metastasis in preclinical models. For instance, U73122 is a common PLC inhibitor that has shown efficacy in reducing cancer cell proliferation. However, the specificity and toxicity of PLC inhibitors need to be carefully evaluated in clinical trials.
